|
| Status |
Public on Nov 26, 2023 |
| Title |
Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Randomized phase II trial patients with early-stage non-small cell lung cancer were treated with either two preoperative cycles of the anti-PD-L1 antibody durvalumab alone or combined with immunomodulatory doses of stereotactic radiation. We report, based on transcriptome analyses of resected tumors, a correlation between an increase of immune pathway genes and freedom from recurrence.
|
| |
|
| Overall design |
RNA-seq studies of resected tumors to identify biomarkers of recurrence in a clinical trial of immune checkpoint blockade therapy in the treatment of non-small cell lung cancer.
|
| |
|
| Contributor(s) |
Altorki NK, McGraw TE, Elemento O, Mittal V, Borczuk A |
| Citation(s) |
38114518, 38401548 |
| |
| Submission date |
Nov 21, 2023 |
| Last update date |
Apr 17, 2024 |
| Contact name |
Olivier Elemento |
| E-mail(s) |
ole2001@med.cornell.edu
|
| Organization name |
Weill Cornell Medicine
|
| Department |
Biochemistry
|
| Street address |
1305 York Ave
|
| City |
New York |
| State/province |
NY |
| ZIP/Postal code |
10021 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
| Samples (29)
|
|
| Relations |
| BioProject |
PRJNA1043632 |
Less...
More...